EPS Annual Meeting

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

The Ground-BrEAking Electroporation-based inTervention for Atrial Fibrillation (BEAT-AF) treatment project is an initiative funded by the European Commission from the European Union’s Horizon 2020 research and innovation programme, and managed under the European Health and Digital Executive Agency (grant number 945125).1,2 The study was also partly funded by IHU LIRYC ANR-10-IAHU-04. This pioneering 5-year programme commenced on […]

We are sorry to announce the death of one of our valued editorial board members, Dr Richard Heuser (November 17, 1950–May 23, 2024). Richard R Heuser, MD, FACC, FACP, FESC, MSCAI, was an internationally recognized cardiologist, inventor, educator and author, and was a diplomat of the American Board of Cardiovascular Diseases and the American Board […]

Highlights The autonomic nervous system plays a critical role in the aetiopathogenesis of atrial fibrillation (AF). Neuromodulation of the autonomic nervous system has been a topic of increased interest in the management of AF. Ablation of ganglionated plexi, ethanol ablation of the vein of Marshall, renal denervation and pulmonary vein isolation have demonstrated promising results […]

Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment strategies and cutting-edge technologies to critical reviews and original research findings, each contributing to our […]

Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 Cardiac amyloidosis is the exemplar infiltrative cardiomyopathy and is characterized by the deposition of misfolded precursor proteins into […]

Summary Few clinical studies have shown an association between coronary artery disease (CAD) and osteoporosis. This cross-sectional study has shown that, among Indian postmenopausal women, the prevalence of CAD increases across lower bone mineral density categories. Femoral neck osteoporosis confers the higher odds of an underlying CAD. Osteoporosis and coronary artery disease (CAD) represent two […]

Glucagon-like peptide 1 (GLP-1) receptor agonists piqued our interest when Marso et al. demonstrated that liraglutide significantly reduced cardiovascular events (CVEs) in persons with type 2 diabetes mellitus (T2DM) who were at a high cardiovascular (CV) risk compared with placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; ClinicalTrials.gov […]

Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1 Recent estimates suggest that over 40% of these patients continue to have uncontrolled blood pressure (BP) and that […]